Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer
- 26 November 2008
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 65 (1), 105-111
- https://doi.org/10.1016/j.lungcan.2008.10.008
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant ChemotherapyNew England Journal of Medicine, 2006
- Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- Mechanisms and strategies to overcome multiple drug resistance in cancerFEBS Letters, 2006
- Applications of genomics in NSCLCLung Cancer, 2005
- Management of small-cell lung cancerAnnals of Oncology, 2005
- The Role of ABC Transporters in Clinical PracticeThe Oncologist, 2003
- Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agentBritish Journal of Cancer, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000